Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Ariad Pharmaceuticals, Inc.    ARIA   US04033A1007

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Ariad Pharmaceuticals, Inc. : ARIA, XOMA, PRAN and NIHD added to NASDAQ Active Stock Watch List at EPR

10/31/2013 | 10:15am US/Eastern

New York, NY - (ACCESSWIRE) - 10/31/2013 - Equity Profile Report initiates its NASDAQ Active Stock Weekly Watch List adding Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), XOMA Corporation (NASDAQ:XOMA), Prana Biotechnology Limited (NASDAQ:PRAN) and NII Holdings Inc. (NASDAQ:NIHD)

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients is currently down (-38.13%) on 26,575,426 shares traded after Ariad suspended sales of cancer pill Iclusig. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) is currently down (-90.81%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=ARIA&SubId=AW

XOMA Corporation (NASDAQ:XOMA) a company that discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific is currently up (+4.35%) on 712,280 shares traded after XOMA Corporation announced very encouraging results from two Phase 2 clinical studies that are part of the Company's broad gevokizumab proof-of-concept program. XOMA Corporation (NASDAQ:XOMA) is currently up (+95.78%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about XOMA Corporation (NASDAQ:XOMA)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=XOMA&SubId=AW

Prana Biotechnology Limited (NASDAQ:PRAN) a company that researches and develops therapeutic drugs for the treatment of neurological disorders in Australia is currently up (+1.80%) on 563,051 shares traded after Prana's PBT2 Reversed Memory Loss in Normal Aging. Prana Biotechnology Limited (NASDAQ:PRAN) is currently up (+161.31%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Prana Biotechnology Limited (NASDAQ:PRAN)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=PRAN&SubId=AW

NII Holdings Inc. (NASDAQ:NIHD) a company that through its subsidiaries, provides wireless communication services under the Nextel brand name to businesses and individuals in Mexico, Brazil, Argentina, Peru, and Chile is currently down (-19.58%) on 2,272,972 shares traded after NII Holdings, Inc. Discussed Q3 2013 Results. NII Holdings Inc. (NASDAQ:NIHD) is currently down (-61.3%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about NII Holdings Inc. (NASDAQ:NIHD)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=NIHD&SubId=AW

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.equityprofilereport.com/

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com


© Accesswire 2013
Latest news on ARIAD PHARMACEUTICALS, INC
1d ago ARIAD PHARMACEUTICALS : Updates on Adoption of Final Opinion for Iclusig
6d ago ARIAD PHARMACEUTICALS : Other Events (form 8-K)
6d ago ARIAD PHARMACEUTICALS : Announces Adoption of Final Opinion for Iclusig by Commi..
10/22 ARIAD PHARMACEUTICALS : Announces Recommendation for Iclusig by the Pharmacovigi..
10/15 ARIAD PHARMACEUTICALS : and Bellicum Announce Revised License Agreement for 's C..
10/15 ARIAD PHARMACEUTICALS : to Webcast Conference Call on Third Quarter 2014 Financi..
10/10 ARIAD PHARMACEUTICALS : Announces Recommendation for Iclusig by the Pharmacovigi..
10/10 ARIAD PHARMACEUTICALS : Entry into a Material Definitive Agreement, Financial St..
10/08 ARIAD PHARMACEUTICALS : AP26113 Receives FDA Breakthrough Therapy Designation Fo..
10/08 ARIAD PHARMACEUTICALS : Presents Updated Clinical Data on AP26113 in Patients wi..
Advertisement
Chart
Duration : Period :
Ariad Pharmaceuticals, Inc Technical Analysis Chart | ARIA | US04033A1007 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF